The undisclosed price deal folds a 347 antibody protein panel into 10x's single cell and spatial platforms, with deal structure and integration roadmap to surface in upcoming SEC filings and earnings calls.
For years, single-cell biology has been a story about transcripts. Researchers crack open individual cells, capture the messenger RNA, and reconstruct a molecular census cell by cell. Proteins, the actual machines doing the work, have lived in a different workflow on a different instrument. 10x Genomics is now trying to close that gap in a single acquisition.
10x Genomics has acquired Proteintech Genomics, a life-science tools company founded in 2022, according to Genetic Engineering and Biotechnology News. The deal was announced this month for an undisclosed price, with 10x confirming the acquisition to GEN. The centerpiece is the MultiPro Human Discovery Panel: 347 DNA-barcoded antibodies covering 325 distinct protein targets, profiled alongside transcriptomic measurements from the same individual cells.
For a researcher running a 10x single-cell or spatial workflow, that capability is the practical pitch. A 347-antibody panel that can be added to an existing Chromium or Visium run means protein readouts layered on top of gene expression from the same cells, without splitting the sample or running a separate proteomics assay. The MultiPro chemistry was designed to slot into single-cell workflows, and 10x's stated intent, per GEN, is to combine its scalable single-cell and spatial platforms with Proteintech Genomics' protein-detection capabilities, moving toward a workflow where transcriptomic and proteomic readouts are generated together as a unified molecular portrait per cell.
That capability has been a long-standing request from labs trying to interpret cell state from RNA alone. RNA abundance is an imperfect proxy for protein levels, and the field has built parallel proteomics workflows on mass spectrometry, on antibody panels from Olink and SomaLogic, and on imaging-based approaches. Folding an antibody-based proteomics readout into a single-cell pipeline, which 10x has not previously offered as a native chemistry, is a different kind of move: a platform vendor extending into a workflow that historically required a separate kit, a separate instrument, and a separate analysis pipeline.
The deal lands in a proteomics market that has been consolidating for two years. Olink was acquired by Thermo Fisher in 2024. SomaLogic merged into Standard BioTools in 2024. Seer continues to operate as an independent liquid-biopsy proteomics play. Antibody-based single-cell proteomics, the specific niche MultiPro occupies, is a smaller pond, but the competitive logic is the same: researchers want fewer vendors and fewer assays, and platforms that can deliver both transcript and protein readouts from the same sample have a structural advantage.
For 10x users, the immediate question is integration. The MultiPro panel is not just chemistry; it is a catalog of 347 reagents, a QC pipeline, and a binding-affinity validation stack. Folding that into 10x's commercial organization will require decisions about which antibodies are bundled, how panels are updated as targets are added or retired, and whether the workflow will be supported on both Chromium (droplet-based) and Xenium and Visium (imaging-based) platforms. 10x has not yet published a public integration roadmap, and the undisclosed price leaves deal structure, financing, and any contingent payments to be detailed in subsequent SEC filings, likely an 8-K.
There are reasons to be cautious. Proteintech Genomics is a young company, founded in 2022, and the MultiPro Human Discovery Panel is its flagship product. Single-product acquisitions carry concentration risk: if the panel underperforms on third-party benchmarks, or if competing antibody panels from BioLegend, Abcam, or newer entrants win on specificity or cost, the strategic rationale weakens. 10x's investor base will also be watching for any 8-K disclosure of deal terms, which will reveal whether the acquisition was a tuck-in, a technology-licensing equivalent, or a more substantial bet.
What to watch next: 10x's next earnings call or investor day, where integration timelines and updated platform roadmaps typically surface; the 8-K filing that will report deal structure and price; and whether MultiPro panels are extended to Xenium and Visium spatial platforms, or remain Chromium-only. If 10x extends protein detection to its imaging products, the deal becomes a true multiomics platform play. If the panel stays confined to droplet-based single-cell, the acquisition is a narrower capability add, an antibody catalog and a chemistry stack layered onto a workflow that 10x already had.
For researchers, the practical question is whether their lab's existing 10x workflow can now answer questions that previously required a separate proteomics grant and a different instrument. The answer, in principle, is yes. Whether the chemistry performs as advertised across diverse sample types, and whether 10x can support it at scale, is what the next year of benchmarking will decide.